Literature DB >> 7875746

Recombinant L7/L12 ribosomal protein and gamma-irradiated Brucella abortus induce a T-helper 1 subset response from murine CD4+ T cells.

S C Oliveira1, Y Zhu, G A Splitter.   

Abstract

Immunity to Brucella abortus crucially depends on antigen (Ag)-specific T-cell mediated activation of macrophages, which are the major effectors of cell-mediated killing of this organism. Ribosomal preparations have been used as vaccines against several pathogens, including B. abortus, conferring a high degree of protection. In the present study, we have examined the pattern of T-helper (Th) cell response from infected BALB/c mice after in vitro stimulation with recombinant (r) L7/L12 ribosomal protein or gamma-irradiated B. abortus. In addition to Ag-specific proliferation, CD4+ T cells were tested for interleukin-2 (IL-2), IL-4 and interferon-gamma (IFN-gamma) mRNA expression and secretion. Detection of cytokine transcripts and secreted cytokines was performed using reverse transcriptase (RT)-polymerase chain reaction (PCR) and specific ELISA assays. Primed CD4+ T cells proliferated to the recombinant protein or whole B. abortus. The functional cytokine profile of the proliferating cells was typical of a Th1 cell phenotype, as we detected transcripts for IL-2 and IFN-gamma but not IL-4. Among the cytokines analysed, only IFN-gamma produced in the Th cell culture supernatants was detected by ELISA when bacteria or recombinant protein were used. Thus, rL7/L12 ribosomal protein and gamma-irradiated B. abortus preferentially stimulated IFN-gamma-producing Th1 cells after in vitro stimulation. The results of this study provide for the first time an explanation of why ribosomal vaccines may protect against intracellular infections, and an experimental basis for identifying polypeptides from a pathogen which stimulates the desired cytokine profile and Th cell response crucial for the design of genetically engineered candidate vaccines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7875746      PMCID: PMC1415073     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

Review 1.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  Vectors that facilitate the expression and purification of foreign peptides in Escherichia coli by fusion to maltose-binding protein.

Authors:  C di Guan; P Li; P D Riggs; H Inouye
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

3.  Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S).

Authors:  J Hu-Li; J Ohara; C Watson; W Tsang; W E Paul
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

4.  Antigens of Brucella abortus S19 immunodominant for bovine lymphocytes as identified by one- and two-dimensional cellular immunoblotting.

Authors:  B M Brooks-Worrell; G A Splitter
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

5.  Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.

Authors:  T F Gajewski; F W Fitch
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

6.  Immunological properties of ribosomal proteins from Mycobacterium bovis BCG.

Authors:  S Tantimavanich; S Nagai; H Nomaguchi; M Kinomoto; N Ohara; T Yamada
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

7.  Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus.

Authors:  L N Araya; P H Elzer; G E Rowe; F M Enright; A J Winter
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

8.  Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones.

Authors:  E Maggi; P Parronchi; R Manetti; C Simonelli; M P Piccinni; F S Rugiu; M De Carli; M Ricci; S Romagnani
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

9.  Cytokine response of T-cell subsets from Brucella abortus-infected mice to soluble Brucella proteins.

Authors:  Y Zhan; J Yang; C Cheers
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

10.  IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.

Authors:  P Scott
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

View more
  15 in total

1.  Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.

Authors:  Mary Philip; Andrea Schietinger; Hans Schreiber
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

2.  Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice.

Authors:  Deyan Luo; Bing Ni; Peng Li; Wei Shi; Songle Zhang; Yue Han; Liwei Mao; Yangdong He; Yuzhang Wu; Xiliang Wang
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Brucella abortus ΔrpoE1 confers protective immunity against wild type challenge in a mouse model of brucellosis.

Authors:  Jonathan W Willett; Julien Herrou; Daniel M Czyz; Jason X Cheng; Sean Crosson
Journal:  Vaccine       Date:  2016-08-31       Impact factor: 3.641

4.  Delayed-type hypersensitivity activity of the Brucella L7/L12 ribosomal protein depends on posttranslational modification.

Authors:  G Bachrach; M Banai; Y Fishman; H Bercovier
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

5.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides.

Authors:  Purushottam Kaushik; Dhirendra K Singh; S Vinoth Kumar; Ashok K Tiwari; Gunjan Shukla; Shanker Dayal; Pallav Chaudhuri
Journal:  Vet Res Commun       Date:  2009-12-16       Impact factor: 2.459

7.  Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51.

Authors:  R Vemulapalli; A J Duncan; S M Boyle; N Sriranganathan; T E Toth; G G Schurig
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

8.  Use of S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol as an adjuvant improved protective immunity associated with a DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus in mice.

Authors:  Angello Retamal-Díaz; Roberto Riquelme-Neira; Darwin Sáez; Alejandra Rivera; Pablo Fernández; Alex Cabrera; Carlos A Guzmán; Angel Oñate
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

9.  Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells.

Authors:  Carola Muñoz-Montesino; Edilia Andrews; Rodolfo Rivers; Andrés González-Smith; Gustavo Moraga-Cid; Hugo Folch; Sandra Céspedes; Angel A Oñate
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

10.  Registered Influenza Viral Vector Based Brucella abortus Vaccine for Cattle in Kazakhstan: Age-Wise Safety and Efficacy Studies.

Authors:  Sholpan Ryskeldinova; Nadezhda Zinina; Zhailaubay Kydyrbayev; Bolat Yespembetov; Yerken Kozhamkulov; Dulat Inkarbekov; Nurika Assanzhanova; Aigerim Mailybayeva; Dina Bugybayeva; Makhpal Sarmykova; Berik Khairullin; Kairat Tabynov; Aitbay Bulashev; Batyrbek Aitzhanov; Khairulla Abeuov; Abylay Sansyzbay; Tlektes Yespolov; Gourapura J Renukaradhya; Steven Olsen; Angel Oñate; Kaissar Tabynov
Journal:  Front Cell Infect Microbiol       Date:  2021-07-01       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.